Renagel
Product Images NDC 17856-0021

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Renagel (NDC 17856-0021). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corps, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1. Chemical Structure Of Sevelamer Hydrochloride (Renagel Figure 1)

Figure 1. Chemical Structure Of Sevelamer Hydrochloride (Renagel Figure 1)
This text appears to be a list of chemical compounds or components. However, without additional context or formatting, it is not possible to provide a useful description.*
FDA Label Image

Figure 2. Percentage Of Patients (y-axis) Attaining A Phosphorus Reduction From Baseline (mg/dl) At Least As Great As The Value Of The X-axis. (Renagel Figure 2)

Figure 2. Percentage Of Patients (y-axis) Attaining A Phosphorus Reduction From Baseline (mg/dl) At Least As Great As The Value Of The X-axis. (Renagel Figure 2)
This appears to be a graph or chart displaying data on the percentage of patients who showed reductions in serum phosphorus levels after treatment with Sevelamer Hydrochloride. The x-axis indicates the reduction in serum phosphorus levels in mg/dL, while the y-axis shows the percentage of patients with reductions greater than a certain threshold "X". The chart also shows whether patients improved, worsened, or had no change in their serum phosphorus levels. However, without additional context, it is difficult to determine the specific values or meaning of the data presented.*
FDA Label Image

Figure 3. Mean Phosphorus Change From Baseline For Patients Who Completed 52 Weeks Of Treatment (Renagel Figure 3)

Figure 3. Mean Phosphorus Change From Baseline For Patients Who Completed 52 Weeks Of Treatment (Renagel Figure 3)
FDA Label Image

Label Image (Rspl17856 0021)

Label Image (Rspl17856 0021)
Renagel is a prescription-only medication that contains sevelamer hydrochloride in its 800 mg tablet form. It was manufactured by Genzyme under the lot number XO000XX and has an expiration date of 10/07/2014. Renagel is distributed by Atlantic Biologics and was packaged by UDOSE in Miami, FL.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.